International Journal of Chronic Obstructive Pulmonary Disease最新文献

{"title":"Observational and Genetic Evidence Reveals the Effect of Serum Lipid Levels on COPD Risk.","authors":"Guobing Jia, Tao Guo, Lei Liu, Chengshi He","doi":"10.2147/COPD.S503030","DOIUrl":"10.2147/COPD.S503030","url":null,"abstract":"<p><strong>Background: </strong>Disorders of lipid metabolism are linked to an increased risk of various diseases; however, their association with chronic obstructive pulmonary disease (COPD) remains unclear. This study aimed to examine the relationship between serum lipid levels and COPD risk.</p><p><strong>Methods: </strong>The methods of the National Health and Nutrition Examination Survey (NHANES) and Mendelian randomization (MR) analyses were employed to investigate the relationships between lipids and COPD across multiple populations. Data from 2013 to 2023 were selected for the NHANES study on US population, and weighted multivariable-adjusted logistic regression was employed as the primary statistical method. And data utilized for the MR analysis were derived from genome-wide association studies (GWAS) conducted on European and East Asian populations, with inverse-variance weighted (IVW) method serving as the principal statistical approach.</p><p><strong>Results: </strong>The NHANES analyses indicated that higher levels of total cholesterol (TC) (OR = 0.85, 95% CI = 0.77-0.93), non-high-density lipoprotein cholesterol (non-HDL-C) (OR = 0.86, 95% CI = 0.78-0.94) and low-density lipoprotein cholesterol (LDL-C) (OR = 0.85, 95% CI = 0.74-0.97) were associated with a reduced risk of COPD in the US population. In the MR analyses, TC (OR = 0.90, 95% CI = 0.84-0.95), non-HDL-C (OR = 0.91, 95% CI = 0.85-0.96), and LDL-C (OR = 0.88, 95% CI = 0.82-0.94) were causally linked to a decreased risk of COPD in the European population. Similar associations were observed in the East Asian population.</p><p><strong>Conclusion: </strong>Our study identified associations between TC, non-HDL-C, and LDL-C with a reduced risk of COPD. This underscores the importance of monitoring lipid metabolism in patients with COPD and provides supporting evidence for the use of lipid-based therapies in its treatment.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2705-2714"},"PeriodicalIF":3.1,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144818053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TFR1 as a Biomarker of Pulmonary Fibrosis Development in COPD Patients.","authors":"Yuan Wu, Yu Jiang, Bin Xiao, Lijun Xie, Nanjiang Zhou, Aoguo Zeng, Cuizhong Liu","doi":"10.2147/COPD.S527782","DOIUrl":"10.2147/COPD.S527782","url":null,"abstract":"<p><strong>Background: </strong>Ferroptosis is involved in chronic lung injury, including COPD and pulmonary fibrosis. In this study, we investigated the role of transferrin protein 1 (TFR1), as a ferroptosis marker, in the development of COPD-associated pulmonary fibrosis.</p><p><strong>Methods: </strong>The expression of TFR1 was elevated in 97 patients with COPD. The correlation analysis of the clinical characteristic was performed including the frequency of acute exacerbation, the fibrosis score, etc. and the expression of TFR1. Animal experiments were carried out to verify TFR1 expression in a rat COPD model.</p><p><strong>Results: </strong>The results showed that the expression of TFR1 was related to DLCO%, 6 MWT, GOLD grade, frequency of acute exacerbation and fibrosis score. Together, in the rat COPD model, higher TFR1 was related to a higher lung injury score and a higher lung fibrosis score.</p><p><strong>Conclusion: </strong>In summary, these results indicated that serum TFR1 levels related to the severity of pulmonary fibrosis in clinical practice and may provide a potential target for the treatment of pulmonary fibrosis development from patients with COPD in the future.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2715-2725"},"PeriodicalIF":3.1,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144818054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breath and Bottle: Evaluating Pharmacotherapy for Alcohol Use Disorder on COPD Exacerbation Outcomes.","authors":"Teng Zhang, Qin Ding, Mengmeng Liu, Yanning Song, Lvfeng Zhang, Na Liang, Xia Zhao, Qian Wang, Xueli Guo, Guangmei Yang, Hongwei Zhang, Wei Chen","doi":"10.2147/COPD.S524905","DOIUrl":"10.2147/COPD.S524905","url":null,"abstract":"<p><strong>Background: </strong>The role of pharmacotherapy for alcohol use disorder (AUD) in mitigating COPD exacerbations remains underexplored. This study aims to evaluate the impact of AUD pharmacotherapy on COPD-related clinical outcomes.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted on 635 COPD patients with comorbid AUD. Patients were categorized into two groups based on whether they received medication for AUD (MAUD group) or not (no-MAUD group). Data on demographics, COPD severity, exacerbation rates, and AUD treatment were extracted from electronic medical records.</p><p><strong>Results: </strong>Individuals in the MAUD group (n=229) exhibited a substantially reduced frequency of COPD exacerbations when compared to those in the non-MAUD group (n=406), with a significant difference observed (<i>P</i><0.001). Additionally, the MAUD group experienced a longer duration before the first exacerbation event (<i>P</i><0.001).</p><p><strong>Conclusion: </strong>Pharmacotherapy for AUD appears to have a protective effect against the occurrence of COPD exacerbations and improved clinical outcomes in patients with comorbid AUD. These findings suggest that AUD treatment should be considered as part of a comprehensive management strategy for COPD patients with AUD.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2697-2704"},"PeriodicalIF":3.1,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12333649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144818051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, Regional, and National Burden Trends in Chronic Obstructive Pulmonary Disease Attributable to Particulate Matter Pollution: 1990-2021 and Projections to 2036.","authors":"Hongxia Duan, Peijun Li, Yingqi Wang, Linhong Jiang, Yide Wang, Weibing Wu, Xiaodan Liu","doi":"10.2147/COPD.S527263","DOIUrl":"10.2147/COPD.S527263","url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, of which 41.27% of the burden may be related to particulate matter (PM) pollution. Understanding the PM-related burden of COPD at global, national and regional levels can provide evidence for public health policies.</p><p><strong>Methods: </strong>First, the numbers of death and disability-adjusted life year (DALY), and the corresponding age-standardized rates were assessed globally and by subtype, including age, sex, sociodemographic index (SDI), country, and region from 1990 to 2021. Second, the temporal trend in disease burden was estimated by joinpoint regression analysis. Furthermore, an international health inequality analysis was used to assess the inequality slope indices and concentration indices, and frontier analysis was performed to explore the current situation and potential improvement of disease burden control. Finally, we constructed an auto regressive integrated moving average model to predict PM-related burden of COPD in the next 15 years.</p><p><strong>Results: </strong>In 2021, the number of COPD deaths and DALYs attributed to PM were approximately 1.54 million and 33.24 million, respectively. The age-standardized death rate (ASMR) and age-standardized DALY rate (ASDR) were 1.66 and 1.50 times higher in males than in females. Interestingly, the ASMR and ASDR exhibited an increase from 2020 to 2021. The highest COPD burden attributed to PM was in low and low-middle SDI regions. Countries with an SDI between 0.3 and 0.6 had the greatest potential to reduce the COPD burden attributed to PM, especially in Asia, Oceania, and Africa. In the next 15 years, the ASMR and ASDR of COPD attributable to PM for both sexes will decrease, and the difference between male and female patients will be almost nonexistent.</p><p><strong>Conclusion: </strong>The COPD burden attributable to PM remains a long-term problem globally, especially in males, the older adults, and low and low-middle SDI regions.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2671-2683"},"PeriodicalIF":3.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12324956/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144795814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cigarette Smoke Extract-Induced Necroptosis Causes Mitochondrial DNA Release and Inflammation of Bronchial Epithelial Cells.","authors":"Kenji Mizumura, Ryosuke Ozoe, Yosuke Nemoto, Naho Furusho, Yusuke Kurosawa, Yutaka Kozu, Takashi Oki, Shuichiro Maruoka, Yasuhiro Gon","doi":"10.2147/COPD.S523610","DOIUrl":"10.2147/COPD.S523610","url":null,"abstract":"<p><strong>Purpose: </strong>Chronic obstructive pulmonary disease (COPD) is characterized by airway inflammation and structural changes in the lungs, including emphysema. Cigarette smoke exposure induces mitochondrial damage, necroptosis-mediated pulmonary epithelial cell death, and emphysematous changes. However, the association between these events and airway inflammation remains unclear. Here, we focused on mitochondrial DNA (mtDNA) as a second messenger linking mitochondrial damage to airway inflammation, aiming to elucidate the mechanisms underlying extracellular mtDNA release and its role in airway inflammation.</p><p><strong>Methods: </strong>Human bronchial epithelial BEAS-2B cells were exposed to cigarette smoke extract and the release of mtDNA into the cytoplasm and extracellular space was examined. Real-time polymerase chain reaction was used to measure mtDNA levels. To examine the involvement of necroptosis, a necroptosis inhibitor (Nec-1) and mitochondria-targeted antioxidant (MitoQ) were used. To evaluate the inflammatory response induced by extracellular mtDNA, we quantified the levels of specific cytokines-interleukin (IL)-6 and IL-8-in the cell culture supernatants after mtDNA transfection, as these mediators are widely accepted as key markers of inflammation in bronchial epithelial cells.</p><p><strong>Results: </strong>Cigarette smoke extract treatment induced the translocation of mtDNA from the mitochondria to the cytoplasm in BEAS-2B cells, followed by its extracellular release. Nec-1 and MitoQ inhibited the extracellular release of mtDNA without affecting its cytoplasmic translocation. Introducing mtDNA into BEAS-2B cells markedly elevated IL-6 and IL-8 levels, indicating that mtDNA may play a pro-inflammatory role.</p><p><strong>Conclusion: </strong>Necroptosis facilitated the release of extracellular mtDNA after cigarette smoke extract exposure, establishing a connection between mitochondrial damage and airway inflammation. mtDNA acted as a pro-inflammatory mediator by inducing cytokine production in pulmonary epithelial cells. These findings suggest that targeting necroptosis could offer a novel therapeutic strategy for COPD by addressing both airway inflammation and structural lung damage.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2685-2695"},"PeriodicalIF":3.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12323784/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144790495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diaphragm Assessment by Multimodal Ultrasound Imaging in Patients with Chronic Obstructive Pulmonary Disease: A Prospective Observational Study.","authors":"Tianjie Zhang, Yan Liu, Mengmei Wang, Miao He, Min Yu, Yi Li, Ye Song","doi":"10.2147/COPD.S527119","DOIUrl":"10.2147/COPD.S527119","url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) patients often exhibit diaphragmatic dysfunction which can be effectively assessed using ultrasonography. This study aims to evaluate diaphragmatic function in COPD patients through multimodal ultrasound imaging and to identify key parameters.</p><p><strong>Methods: </strong>This study consecutively enrolled 75 COPD patients and 75 healthy subjects. Measurements of diaphragm contraction, motion-related parameters and tissue Doppler imaging (TDI) parameters were conducted and recorded. Clinically relevant data were collected. Baseline demographics, spirometry results, and ultrasound data were compared between COPD patients and healthy subjects. Receiver Operating Characteristic (ROC) curve was constructed to evaluate the diagnostic value of diaphragmatic ultrasound parameters for COPD patients.</p><p><strong>Results: </strong>Diaphragm at the end of tidal inspiration (DT_insp), diaphragm thickening fraction (DTF), diaphragmatic excursion during deep breathing (DE_DB) were significantly lower in COPD patients than in healthy subjects, conversely diaphragmatic excursion during quiet breathing (DE_QB), diaphragmatic contraction velocity during quiet breathing (DCV_QB), peak contraction velocity(PCV), peak relaxation velocity (PRV), velocity-time integral (VTI) were higher in COPD patients than in healthy subjects. DT_insp, DTF, DE_DB values decreased as COPD severity increased, conversely, DE_QB, DCV_QB, PCV, PRV and VTI exhibited an upward trend with COPD severity. DTF was positively correlated with FEV1 predicted (r=0.713, P=0.000), DE_QB (r=-0.740 and -0.889), PCV (r=-0.609 and -0.778), PRV (r=-0.686 and -0.857) were negatively correlated with FEV1/FVC and FEV1 predicted (P=0.000). Meanwhile, DE_QB, DCV_QB, PCV and PRV exhibited superior performance in predicting COPD, with AUC values of 0.906, 0.833, 0.859 and 0.833, respectively. DE_QB exhibited 81.33% sensitivity, while DTF, DE_QB, DE_DB, PCV and PRV showed high specificity (98.67%, 90.67%, 96.00%, 97.33% and 100%, respectively).</p><p><strong>Conclusion: </strong>Multimodal ultrasound imaging offers a sensitive approach for detecting diaphragmatic dysfunction in COPD patients. Diaphragm ultrasound parameters correlate with pulmonary function and COPD severity, indicating that these parameters can provide valuable insights into disease progression and management.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2629-2638"},"PeriodicalIF":3.1,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12317707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144776614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Patterns and Triple Therapy Utilization in Chinese Patients with Chronic Obstructive Pulmonary Disease: An Analysis of Real-World Data from the Yinzhou Database.","authors":"Yan Chen, Xinli Li, Dongni Hou, Wenhao Li, Zhike Liu, Meng Zhang, IokFai Cheang, Peng Shen, Hongbo Lin, Siyan Zhan, Feng Sun, Yuanlin Song","doi":"10.2147/COPD.S499783","DOIUrl":"10.2147/COPD.S499783","url":null,"abstract":"<p><strong>Purpose: </strong>Triple therapy of chronic obstructive pulmonary disease (COPD), consisting of inhaled corticosteroid (ICS), long-acting β2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) has shown benefits in patients with COPD. However, little is known about the use of triple therapy in Chinese patients. This study aims to describe the treatment patterns and the utilization of triple therapy in COPD patients based on real-world data from China.</p><p><strong>Patients and methods: </strong>This retrospective study included patients with COPD from the Yinzhou database. Patients aged ≥ 40 years with a diagnosis of COPD were included. Different combinations of ICS, LAMA and LABA prescribed during follow-up were categorized as single, dual, or triple therapies. Descriptive analysis was performed to depict the treatment patterns of each therapy.</p><p><strong>Results: </strong>A total of 7888 patients were prescribed at least one COPD therapy during the follow-up. Among them, 29.1% were prescribed triple therapy (ICS+LABA+LAMA) with a median (IQR) treatment duration of 3.27 (7.17) months. The majority (68.6%) of patients were prescribed dual therapy with ICS+LABA, while 27.3% and 23.3% of patients were prescribed single therapy with ICS or LAMA, respectively. Regarding treatment sequences during follow-up, 30.1% of patients received dual therapy with ICS+LABA, followed by 11.4% receiving only triple therapy and 10.4% receiving single therapy with ICS alone.</p><p><strong>Conclusion: </strong>Our study assessed treatment patterns and triple therapy utilization among patients with COPD in China. The majority of patients were treated with ICS+LABA dual therapy. Triple therapy was also widely used, with most patients transitioning from other treatment modalities.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2659-2670"},"PeriodicalIF":3.1,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12317704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144776615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Support Needs of Patients with Chronic Obstructive Pulmonary Disease (COPD) and Asthma Throughout Their Patient Journey: A Qualitative Study.","authors":"Carlos Almonacid, Raquel Gómez, Ignacio Morán, Irantzu Muerza, Mariano Pastor, Paula Garcia-Esparcia, Elena García, Cristina Soria, Esther Lázaro, Dolors Querol","doi":"10.2147/COPD.S526548","DOIUrl":"10.2147/COPD.S526548","url":null,"abstract":"<p><strong>Purpose: </strong>Chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma, pose a significant health risk due to the increasingly pronounced rise in its prevalence, associated complications and impact on patients' quality of life. The aim of this study is to analyse the needs of patients with COPD and asthma throughout their patient journey.</p><p><strong>Patients and methods: </strong>To this end, a qualitative and cross-sectional study was conducted based on interviews and focus groups. 28 people took part, including patients, relatives and representatives of patient associations, and they were selected to ensure a diversity of perspectives. The data collected were analyzed by two psychologists with experience in qualitative research, who conducted thematic analysis and made use of data saturation criteria.</p><p><strong>Results: </strong>The results emphasize that patient needs vary according to the stage of the disease. In the initial stage, patients find it difficult to identify symptoms and risk factors, and demand education on basic concepts and self-care strategies. When diagnosed, they require psycho-emotional support and training on the disease. Insufficient information, particularly concerning the use of inhalers and the different therapies, is a recurrent obstacle in treatment and monitoring. Furthermore, therapeutic nonadherence is affected by factors such as perception of the severity of the disease, related to the treatment and deficiencies in inhaler technique. Additionally, pulmonary rehabilitation and multidisciplinary care are unmet needs that have an impact on patients' quality of life.</p><p><strong>Conclusion: </strong>The study highlights the importance of personalizing interventions according to the stage of the patient journey, combining education, disease coping strategies and comprehensive monitoring. Patient groups play a key role as they are a source of emotional support, guidance and self-care. In conclusion, a proposal is made for a patient-centred approach that promotes self-management, equitable access to resources and coordination between healthcare teams to optimise integrated care in respiratory diseases. In this respect, it seems relevant and appropriate to develop training environments for patients diagnosed with asthma/COPD and their carers, where information and training are offered to support good disease management in the different stages of the patient journey.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2639-2658"},"PeriodicalIF":3.1,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144795815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening and Verification COPD-OSA Overlap Syndrome Core Genes Using Bioinformatics.","authors":"Shihao Qiang, Rongrong Wan, Jingyi Wu, Chao Wang, Xiaochuan Cui, Yunyun Zhang","doi":"10.2147/COPD.S528703","DOIUrl":"10.2147/COPD.S528703","url":null,"abstract":"<p><strong>Background: </strong>When obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD) coexist in a patient, it is called overlap syndrome (OS). However, the molecular mechanisms underpinning OS are unclear. To address this, we explored potential OS mechanisms using bioinformatics.</p><p><strong>Methods: </strong>OSA and COPD gene expression datasets were obtained from the Gene Expression Omnibus (GEO) database. Differential expression and weighted gene co-expression network analyses (WGCNA) were performed to identify common differentially expressed genes (DEGs) in OSA and COPD, and perform functional enrichment analysis. DEGs were validated in an external COPD gene expression dataset using receiver operating characteristic (ROC) curves and box plots. Positive results were initially identified as core genes, and were then validated by analyzing core genes in healthy controls, patients with OSA alone and patients with OS using RT-qPCR.</p><p><strong>Results: </strong>Through differential expression gene analysis, 9 common DEGs for OSA and COPD were identified. Through WGCNA analysis, 128 common key module genes for OSA and COPD were identified. By taking the intersection of the identified 9 DEGs and the 128 common key module genes from WGCNA, 5 key genes were determined. Preliminary validation in the external gene expression dataset for COPD revealed that <i>GRM8</i> was a potential hub gene for OS. Compared with the control group, the expression of <i>GRM8</i> was significantly downregulated in the COPD group (<i>P</i> = 0.019). The diagnostic value was evaluated using the ROC curve, and the results showed that the AUC was 0.857 (95% CI: 0.614-1.000). Finally, RT-qPCR confirmed that the expression levels of <i>GRM8</i> in OSA and OS were significantly lower than those in the healthy control group (<i>P</i> < 0.05), and it was a hub gene significantly associated with OS.</p><p><strong>Conclusion: </strong>Our research identified hub gene that may provide new directions for further mechanistic research on OS.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2601-2614"},"PeriodicalIF":3.1,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12311238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144762050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differentiating Emphysema From Emphysema-Dominated COPD Patients with CT Imaging Feature and Machine Learning.","authors":"Wanjin Guo, Mengqi Li, Ying Li, Xiaole Fan, Lei Wu","doi":"10.2147/COPD.S527914","DOIUrl":"10.2147/COPD.S527914","url":null,"abstract":"<p><strong>Background: </strong>Differentiating between emphysema and emphysema-dominant chronic obstructive pulmonary disease (COPD) remains challenging but crucial for appropriate management. Quantitative computed tomography (QCT) offers potential for improved characterization, yet its optimal application in conjunction with machine learning for this differentiation is not fully established.</p><p><strong>Methods: </strong>This prospective study enrolled 476 participants (99 with emphysema, 377 with emphysema-dominant COPD) aged 34-88 years. All participants underwent spirometry and chest CT scans. QCT features including emphysema index, mean lung density, airway measurements, and vessel measurements were extracted. A random forest model was developed using these QCT features to differentiate between the two groups. The model's performance was assessed using area under the receiver operating characteristic curve (AUC-ROC). Correlations between QCT parameters and pulmonary function tests were analyzed.</p><p><strong>Results: </strong>The model achieved an AUC-ROC of 0.97 (95% CI: 0.96-0.99) in differentiating emphysema from emphysema-dominant COPD. Emphysema index and airway wall thickness were the most important features for classification. QCT-derived emphysema index showed strong negative correlation with FEV1/FVC (<i>ρ</i> = -0.54, p<0.001) in the emphysema-dominant COPD group, but no significant correlation in the emphysema group (<i>ρ</i> = 0.001, p=0.993). Mean lung density was significantly lower in the emphysema-dominant COPD group compared to the isolated emphysema group (p<0.001).</p><p><strong>Conclusion: </strong>Machine learning analysis of QCT features can accurately differentiate emphysema from emphysema-dominant COPD. The differing relationships between QCT parameters and lung function in these two groups suggest distinct pathophysiological processes. These findings may contribute to improved diagnosis, phenotyping, and management strategies in emphysema and COPD.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2615-2628"},"PeriodicalIF":3.1,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144745593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}